文献速递肿瘤 PET/CT

68Ga-P16-093与68Ga-PSMA-617 PET/CT在初诊前列腺癌患者中的头对头比较:一项先导研究

Head-to-Head Comparison of 68 Ga-P16-093 and 68 Ga-PSMA-617 PET/CT in Patients With Primary Prostate Cancer : A Pilot Study.
PubMed 文献 · Clin Nucl Med · 2023-01-20

纳入30例未经治疗的初诊前列腺癌患者,每例在一周内先后行68Ga-P16-093与68Ga-PSMA-617 PET/CT。68Ga-P16-093检出更多阳性肿瘤(67 vs 56,P=0.002),匹配肿瘤SUVmax更高(18.3±14.4 vs 13.9±11.8,P<0.001)。作者认为68Ga-P16-093可能更适合初诊前列腺癌的诊断与分期。

要点

  • 68Ga-P16-093较68Ga-PSMA-617检出更多阳性肿瘤(67 vs 56,P=0.002)
  • 前列腺内病灶(29 vs 24,P=0.025)与淋巴结转移(23 vs 17,P=0.034)均检出更多
  • 68Ga-P16-093的SUVmax与PSMA表达显著相关(r=0.732,P<0.001)

核心结论

  • 68Ga-P16-093 PET/CT较68Ga-PSMA-617 PET/CT显示更高的肿瘤摄取和可能更好的肿瘤检出能力,提示68Ga-P16-093可能更适合初诊前列腺癌患者的诊断与分期。

研究设计与样本

  • 先导研究,纳入30例未经治疗的初诊前列腺癌患者,每例在一周内先后行68Ga-P16-093与68Ga-PSMA-617 PET/CT,行视觉分析、SUV半定量比较及相关性分析。

主要发现

  • 68Ga-P16-093 PET/CT检出阳性肿瘤67个 vs 68Ga-PSMA-617 PET/CT 56个(P=0.002)。
  • 前列腺内病灶68Ga-P16-093检出29个 vs 68Ga-PSMA-617检出24个(P=0.025);淋巴结转移68Ga-P16-093检出23个 vs 68Ga-PSMA-617检出17个(P=0.034)。
  • 匹配肿瘤SUVmax:68Ga-P16-093为18.3±14.4 vs 68Ga-PSMA-617为13.9±11.8(P<0.001)。
  • 按D'Amico分级,高危患者68Ga-P16-093的SUVmax为20.9±9.9 vs 低危8.9±9.1 vs 中危10.1±5.2(P=0.007)。
  • 68Ga-P16-093肿瘤SUVmax与活检Gleason评分(r=0.462,P=0.005)及前列腺特异性抗原值(r=0.491,P=0.002)呈中度相关,与PSMA表达显著相关(r=0.732,P<0.001)。

关键数值与推荐

  • 68Ga-P16-093与68Ga-PSMA-617 PET/CT在初诊前列腺癌中的阳性肿瘤检出数分别为67个与56个(P=0.002)。
  • 匹配肿瘤SUVmax分别为18.3±14.4与13.9±11.8(P<0.001)。
  • 高危、低危、中危患者68Ga-P16-093的SUVmax分别为20.9±9.9、8.9±9.1、10.1±5.2(P=0.007)。

临床怎么用

  • 作者认为68Ga-P16-093可能更适合初诊前列腺癌患者的诊断与分期(原文语气为may be more suitable)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aimed to compare the diagnostic performance of 68 Ga-P16-093 and 68 Ga-PSMA-617 PET/CT in primary prostate cancer (PCa) patients. PATIENTS AND METHODS: Thirty untreated primary PCa patients were enrolled. Each patient underwent 68 Ga-P16-093 and 68 Ga-PSMA-617 PET/CT within a week. In addition to visual analysis, SUV was measured for semiquantitative comparison and correlation analysis. RESULTS: 68 Ga-P16-093 PET/CT detected more positive tumors than 68 Ga-PSMA-617 PET/CT (67 vs 56, P = 0.002), especially for intraprostatic lesions (29 vs 24, P = 0.025) and lymph node metastases (23 vs 17, P = 0.034). Further, 68 Ga-P16-093 PET/CT exhibited significantly higher SUV max of matched tumors (18.3 ± 14.4 vs 13.9 ± 11.8, P < 0.001). Besides, the SUV max of high-risk patients (based on D'Amico classification) on 68 Ga-P16-093 PET/CT was significantly higher than that of low- and intermediate-risk PCa patients (20.9 ± 9.9 vs 8.9 ± 9.1 vs 10.1 ± 5.2, P = 0.007). The SUV max of tumor measured by 68 Ga-P16-093 PET/CT had a moderate association with biopsy Gleason score ( r = 0.462, P = 0.005) and prostate-specific antigen value ( r = 0.491, P = 0.002), and significantly correlated with PSMA expression ( r = 0.732, P < 0.001). CONCLUSIONS: 68 Ga-P16-093 PET/CT exhibited higher tumor uptake and potentially better tumor detection capability than 68 Ga-PSMA-617 PET/CT, which suggested that 68 Ga-P16-093 may be more suitable in the diagnosis and staging of primary PCa patients.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Wang G, Li L, Zang J, et al. Head-to-Head Comparison of 68 Ga-P16-093 and 68 Ga-PSMA-617 PET/CT in Patients With Primary Prostate Cancer : A Pilot Study. Clin Nucl Med. 2023. PMID: 36727866. doi:10.1097/RLU.0000000000004566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。